Commentary: pediatric antifungal drug development: lessons learned and recommendations for the future.

about

Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.Pharmacokinetics and pharmacodynamics of antibacterials, antifungals, and antivirals used most frequently in neonates and infants.

P2860

Q38193337-74E117FF-2C08-4FEE-BF76-D01B87477343 Q38215682-8F6EE0DE-0D72-4B71-9DAE-212CCE8B82EE

P2860

Commentary: pediatric antifungal drug development: lessons learned and recommendations for the future.

Item

http://www.wikidata.org/entity/Q35973357

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Commentary: pediatric antifung ...... ecommendations for the future.

@ast

Commentary: pediatric antifung ...... ecommendations for the future.

@en

type

Item

label

Commentary: pediatric antifung ...... ecommendations for the future.

@ast

Commentary: pediatric antifung ...... ecommendations for the future.

@en

prefLabel

Commentary: pediatric antifung ...... ecommendations for the future.

@ast

Commentary: pediatric antifung ...... ecommendations for the future.

@en

P1476

Commentary: pediatric antifung ...... ecommendations for the future.

@en

P2093

Daniel K Benjamin

http://www.w3.org/2001/XMLSchema#string

Kevin M Watt

http://www.w3.org/2001/XMLSchema#string

Michael Cohen-Wolkowiez

http://www.w3.org/2001/XMLSchema#string

Robert M Ward

http://www.w3.org/2001/XMLSchema#string

P2860

Safety and pharmacokinetics of repeat-dose micafungin in young infants.

Pharmacokinetics of an elevated dosage of micafungin in premature neonates.

In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species.

Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients.

Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model.

Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model

Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children.

Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models.

Impact of antimicrobial dosing regimen on evolution of drug resistance in vivo: fluconazole and Candida albicans.

In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model.

P304

635-637

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/INF.0B013E31824F8426

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22414903

http://www.w3.org/2001/XMLSchema#string

P932

3356443

http://www.w3.org/2001/XMLSchema#string

Commentary: pediatric antifungal drug development: lessons learned and recommendations for the future.

about

P2860

P2860

Commentary: pediatric antifungal drug development: lessons learned and recommendations for the future.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932